The microbiome as an active modulator of aging is a fascinatng angle that hasn't gotten enough atention. Treating dysbiosis as a driver of inflammaging rather than just a symptom could reframe how we think about longevity interventions at a fundamntal level.
Thank you for your comment, agree. I heard this same sentiment at several relevant conferences this autumn, and there is mounting evidence that the microbiome could be the next frontier for antiaging therapeutic discovery, which is, of course, quite exciting!
The microbiome as an active modulator of aging is a fascinatng angle that hasn't gotten enough atention. Treating dysbiosis as a driver of inflammaging rather than just a symptom could reframe how we think about longevity interventions at a fundamntal level.
Thank you for your comment, agree. I heard this same sentiment at several relevant conferences this autumn, and there is mounting evidence that the microbiome could be the next frontier for antiaging therapeutic discovery, which is, of course, quite exciting!
Longevity Biotechnology is the next big thing - GLP1s just paved the way!
Thank you for your comment, indeed seems like a tectonic shift in the pharma space these days...